EX-99.1
Open exhibit ↗Current Report · Items 7.01, 9.01 · 8-K
Abeona Therapeutics Inc.
ABEONASDAQEQUITYCurrent
Regulation FD Disclosure
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Description No. ───────────────────────────────────────────────────────────────────────────────────────────────────────────── 99.1 Abeona Therapeutics Inc. Presentation, dated June 10, 2026, entitled “Investor Presentation” 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Company context
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN® (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated for a variety of devastating diseases. For more information, visit www.abeonatherapeutics.com.
Current securities
Historical securities (1)
Disclosure sections
Item 9.01Item 9.01 - Financial Statements and Exhibits
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit Description
No.
─────────────────────────────────────────────────────────────────────────────────────────────────────────────
99.1 Abeona Therapeutics Inc. Presentation, dated June 10, 2026, entitled “Investor Presentation”
104 Cover
Page Interactive Data File (embedded within the Inline XBRL document)